anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Assessment of the psychometric characteristics of the Greek version of the brief World Health Organization Quality of Life Instrument (WHOQOL-BREF) in patients with advanced cancer and pain, and exploration of the association between psychological distress and quality of life (QoL).
METHOD: The sample consisted of 145 patients with advanced cancer and pain who completed the WHOQOL-BREF, the Symptom Checklist-90 (SCL-90), and the Pain Visual Analogue Scale (VAS). In analysis, the following methods were used: Cronbach's alpha, Item Response Theory (IRT), polychoric, Pearson and polyserial correlation, t-test, and Linear regression.
RESULTS: The internal consistency was high for all domains of the WHOQOL-BREF (Cronbach's α ≥ 0.731). Similarly, with the exception of three items, the WHOQOL-BREF items has large discrimination parameters suggesting that they have a high ability in differentiating subjects. On SCL-90, the three dimensions with the highest scores were Depression, Somatization, and Anxiety. The overall score for psychological distress, the Global Severity Index (GSI), showed significant negative association with all the WHOQOL-BREF factor scores (Physical Health: B = -1.488, p < 0.001, Psychological Health: B = -1.688, p < 0.001, Social Relationships: B = -0.910, p < 0.001, Environment: B = -1.064, p < 0.001). Male gender was associated with lower scores for Social Relationships (B = -0.358, p = 0.007) and Environment (B = -0.293, p = 0.026).
SIGNIFICANCE OF RESULTS: The Greek version of the WHOQOL-BREF showed good psychometric properties in patients with advanced cancer and can be used as a reliable instrument in clinical practice. The level of psychological distress can be considered a determinant of QoL in patients with advanced cancer and pain, independently of pain intensity or other clinical characteristics. In cancer, the disease process can activate multiple physiological and psychological mechanisms that lead to a wide range of symptoms of psychological distress. To improve their QoL, psychological intervention focused on the identification and alleviation of psychological distress in patients with advanced cancer, and help in finding meaning in their experience, should be provided.
Escitalopram 10 mg capsule, orally, once daily increased to 20 mg/day at the Week 1 (end of Week 1) based upon tolerability profile, for 8 weeks. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
A health care management method and system are used to relieve health care personnel of the burden of administrative, regulatory and reimbursement tasks which distract them from practicing medicine. The system includes a central database and at least one portable user interface device. The central database stores a plurality of medical records associated with a plurality of patients. The portable user interface device includes a display and a memory. A subset of the plurality of medical records is stored in the memory of the portable user interface device. The portable user interface device presents on the display a plurality of selectable windows including at least one activity initiation window for ordering health care activities associated with a selected patient and an activity status window for presenting a list of the ordered health care activities and the status of each ordered health care activity.
A method for presenting applications in an interactive service featuring steps for generating screen displays of the service applications at the reception systems of the respective users. Steps are provided for generating the application displays as screens having a plurality of partitions, the partitions being constructed from reusable elements. In accord with the method, the screens include at least a first partition at which an application may be presented and a second, concurrently displayed partition including command functions for managing the display. The method further includes steps for providing command functions that facilitate random navigation to new applications with a variety of different procedures which the user can choose from. In (preferred) one form, the functions are presented as a command bar located at the bottom of the screen. Further, the method includes steps for opening and closing windows on the display to enable presentation of additional data relating to the presented applications. Still further, the method includes steps for providing additional partitions for concurrently displaying other applications, which may include advertising.
The invention discloses a medicine composition for treating scald and belongs to the field of medicine. The medicine composition includes the following components, by weight, 25-40% of phoenix tree leaves, 2-5% of borneol, 25-40% of phoenix tree oil, 4-8% of clerodendrum bungei, 5-17% of Chinese prickly ash oil and 3-7% of mint leaves. The invention also discloses a preparation method and a preparation of the medicine composition. The medicine composition can quickly recover a wound and generate new muscle, so that the wound can heal quickly and a scar can be eliminated. The medicine composition is especially suitable for scalds caused by boiled water, boiled oil and such scalds and various burns. The medicine composition is 100% in effective rate on various scalds and burns, is higher than 98% in curative rate, is almost free of side and toxic effects, is quick in effects, is low in cost, is easy to prepare, is convenient to use and is suitable for being popularized.
The invention discloses a traditional Chinese medicine composition for treating diabetes, a blood circulation promoting and meridian dredging gel composition and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The invention relates to a traditional Chinese medicine composition for treating diabetes mellitus, which is a monarch drug: rhizoma Polygonati, radix astragali, and radix rehmanniae Preparata. Regulating liver, nourishing pancreas, nourishing yin, invigorating kidney; ministerial drugs: ginseng, dried yam, angelica, hemp seed, bitter apricot seed and rhubarb. Auxiliary monarch drug, clearing stomach dryness, enhancing excretion of intestinal toxins, and simultaneously strengthening the activity and dredging collaterals, thereby being beneficial to the monarch drug to enter focus to play a role in treatment and improving the treatment effect. Through clearing intestinal toxin and reducing blood sugar, the intestinal canal is ensured. Through the three-in-one mode, blood sugar is regulated, pathological islet cells and related complications are repaired, yin-yang balance is ensured, and six viscera are operated in coordination and balance. Through innovation, the theory of six viscera and six viscera is provided, and the gel for promoting blood circulation and removing obstruction in collaterals is matched, so that the problem of obstruction of viscera and collaterals is solved, metabolism is promoted, the channels and collaterals are ensured to be removed, qi and blood are removed, and the treatment effect of diabetes is further enhanced.
One group of patients will receive Lasix® (furosemide 40 mg). For treatment, the patient will swallow the tablet in whole form on an empty stomach with some liquid.
Cosmetic cleaning composition in powder form containing, based on the total weight of the composition, a) 10.0 to 70.0 wt.% of at least one ionic surfactant (e.g. amino-acid based surfactants, isethionates, alkyl sulfites), b) 1.0-8.0 weight per cent of at least one C2-C6 polyhydric alcohol (e.g. 1,2-propylene glycol, 1,3-butylene glycol, dipropylene glycol, glycerin, diglycerol, and c) 20.0 to 40.0 % by weight of at least one polysaccharide. The polysaccharide may be a starch fraction, or a derivative of starch such as amylose, amylopectin or dextrin. The powder cleaning composition may further comprise one or more of: lipids; vegetable oils, butters and/or waxes; protein hydrolysates; silicones; plant extracts; anti-dandruff active ingredients. The composition in powder-form is preferably substantially free of water and/or preservatives. Also claimed is a cosmetic process for cleaning the human body and/or hair in which a cosmetic cleansing agent in powder form as described herein is dissolved in water, rubbed and/or foamed between the hands, distributed over the part of the body to be cleansed and rinsed off with water after a contact time of 10 seconds to 15 minutes.
BACKGROUND/AIMS: : The optimal duration and interval of follow-up for cystic lesions of the pancreas (CLPs) is not well established. This study was performed to investigate the optimal duration and interval of follow-up for CLPs in clinical practice.
METHODS: : Patients with CLPs without worrisome features or high-risk stigmata underwent follow-up with computed tomography at 6, 12, 18, and 24 months and then every 12 months thereafter. A retrospective analysis of prospectively collected data was performed.
RESULTS: : A total of 227 patients with CLPs detected from 2000 to 2008 (mean initial diameter, 1.3±0.6 cm) underwent follow-up for a median of 120 months. Twenty-two patients (9.7%) underwent surgery after a median of 47.5 months. Malignancies developed in four patients (1.8%), one within 5 years and three within 10 years. One hundred and fourteen patients (50.2%) were followed up for more than 10 years. No malignancy developed after 10 years of follow-up. During surveillance, 37 patients (16.3%) experienced progression to surgical indication. In patients with CLPs less than 2 cm in diameter, development of surgical indications did not occur within 24 months of follow-up.
CONCLUSIONS: : CLPs should be continuously monitored after 5 years because of the persistent potential for malignant transformation of CLPs. An interval of 24 months for initial follow-up might be enough for CLPs with initial size of less than 2 cm in clinical practice.
Antibiotic resistance is an urgent threat to global health, with the decreasing efficacy of conventional drugs underscoring the urgency for innovative therapeutic strategies. Antimicrobial peptides present as promising alternatives to conventional antibiotics. Gramicidin S is one such naturally occurring antimicrobial peptide that is effective against Staphylococcus aureus, with a minimum inhibitory concentration (MIC) of 4 μg/mL (3.6 μM). Despite this potent activity, its significant hemolytic toxicity restricts its clinical use to topical applications. Herein, we present rational modifications to the key β-strand and β-turn regions of gramicidin S to concurrently mitigate hemolytic effects, while maintaining potency. Critically, peptide 9 displayed negligible hemolytic toxicity, while possessing significant antibacterial potency against a panel of methicillin-sensitive and methicillin-resistant S. aureus clinical isolates (MIC of 8 μg/mL, 7.2 μM). Given the substantial antibacterial activity and near absence of cytotoxicity, 9 presents as a potential candidate for systemic administration in the treatment of S. aureus bacteremia/sepsis.
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disease. The Janus kinase (JAK) has been identified as a target in AD, as it regulates specific inflammatory genes and adaptive immune responses. However, the efficacy of topically applied JAK inhibitors in AD is limited due to the unique structure of skin. We synthesized JAK1/JAK2 degraders (JAPT) based on protein degradation targeting chimeras (PROTACs) and prepared them into topical preparations. JAPT exploited the E3 ligase to mediate ubiquitination and degradation of JAK1/JAK2, offering a promising AD therapeutic approach with low frequency and dosage. In vitro investigations demonstrated that JAPT effectively inhibited the release of pro-inflammatory cytokines and reduced inflammation by promoting the degradation of JAK. In vivo studies further confirmed the efficacy of JAPT in degrading JAK1/JAK2, leading to a significant suppression of type I, II, and III adaptive immunity. Additionally, JAPT demonstrated a remarkable reduction in AD severity, as evidenced by improved skin lesion clearance and AD severity scores (SCORAD). Our study revealed the therapeutic potential of JAPT, surpassing conventional JAK inhibitors in the treatment of AD, which suggested that JAPT could be a promising topically applied anti-AD drug targeting the JAK-STAT signaling pathway.
Alcohol exposure in adolescence is considered a major cause of cognitive impairments later in life including spatial learning and memory. Integrated stress response (ISR), a program of conservative translation and transcription, is crucial in synaptic plasticity and memory. Although previous studies have elucidated ISR in different brain areas involved in learning and memory disorders, the impact of ISR on learning and memory following adolescent alcohol exposure remains unclear. Here, we demonstrated that adolescent intermittent ethanol (AIE) exposure caused spatial learning and memory impairment, combined with neuronal damage in the medial prefrontal cortex (mPFC), nucleus accumbens (NAc) and hippocampus (HIP) in adult rats. Moreover, integrated stress response inhibitor (ISRIB) administration not only improved spatial learning and memory impairment and neuronal damage but also inhibited the endoplasmic reticulum stress (ER) and reversed changes in synaptic proteins. These findings suggested that ISRIB ameliorates AIE exposure-induced spatial learning and memory deficits by improving neural morphology and synaptic function through inhibiting ER stress signaling pathway in the mPFC, NAc and HIP in adulthood. Our findings may enhance comprehension of cognitive function and neuronal effects of adolescent ethanol exposure and ISRIB treatment may be an underlying potential option for addressing alcohol-induced learning and memory deficits.
The present invention relates to an assessment technique which is conveniently practiced on a computer or over a network. The system first initiates a Testlet (302) which includes identification of the test subject and the test session, and it further identifies the group of questions related to a domain. The system then displays a Testlet question (304) with its possible responses on a device. The device then receives the response (306) to the displayed question followed by an evaluation (308) of the response. Finally, the system evaluates the statistical probability of a specific condition of the test subject and compares it against an established threshold limit (310). If the limit has been satisfied, the system may exit the Testlet (312).
Neurontin® (gabapentin) Capsules, Neurontin® (gabapentin) Tablets, and Neurontin® (gabapentin) Oral Solution are supplied as imprinted hard shell capsules containing 100 mg, 300 mg, and 400 mg of gabapentin, elliptical film-coated tablets containing 600 mg and 800 mg of gabapentin or an oral solution containing 250 mg/5 mL of gabapentin.

The inactive ingredients for the capsules are lactose, cornstarch, and talc. The 100 mg capsule shell contains gelatin and titanium dioxide. The 300 mg capsule shell contains gelatin, titanium dioxide, and yellow iron oxide. The 400 mg capsule shell contains gelatin, red iron oxide, titanium dioxide, and yellow iron oxide. The imprinting ink contains FD&C Blue No. 2 and titanium dioxide.

The inactive ingredients for the tablets are poloxamer 407, copolyvidonum, cornstarch, magnesium stearate, hydroxypropyl cellulose, talc, candelilla wax and purified water.

The inactive ingredients for the oral solution are glycerin, xylitol, purified water and artificial cool strawberry anise flavor.

Gabapentin is described as 1-(aminomethyl)cyclohexaneacetic acid with a molecular formula of C9H17NO2 and a molecular weight of 171.24. The structural formula of gabapentin is:

Gabapentin is a white to off-white crystalline solid with a pKa1 of 3.7 and a pKa2 of 10.7. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is –1.25.
BACKGROUND: Computed tomography (CT) is frequently performed in the patients who admitted to the emergency department (ED), discharged but returned to ED within 72 h. It is unknown whether the main complaints of patients assist physicians to use CT effectively. This study aimed to find the association between chief complaints and the CT results.
METHODS: This three-year retrospective cohort study was conducted in the ED of a tertiary medical center. Adult patients who returned to the ED after the index visit were included from 2019 to 2021. Demographics, pre-existing diseases, chief complaints, and CT region were recorded by independent ED physicians. A logistic regression model with an odds ratio (OR) and 95% confidence interval (CI) was used to determine the relationship between chief complaints and positive CT results.
RESULTS: In total, 7,699 patients revisited ED after the index visit; 1,202 (15.6%) received CT. The top chief complaints in patients who received CT were abdominal pain, dizziness, and muscle weakness. Patients with abdominal pain or gastrointestinal symptoms had a significantly higher rate of positive abdominopelvic CT than those without it (OR 2.83, 95% CI 1.98-4.05, p < 0.001), while the central nervous system and cardiopulmonary chief complaints were not associated (or negatively associated) with new positive CT findings.
CONCLUSION: Chief complaints of patients on revisit to the ED are associated with different yields of new findings when CT scans of the chest, abdomen and head are performed. Physicians should consider these differential likelihoods of new positive findings based on these data.
Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m\^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
The present invention includes compositions and drying methods for preserving sensitive bioactive materials in storage, a method for preparing the composition and preparations containing the composition, wherein the preparations are delivered through mouths. The invention provides a dry composition for stabilization. The composition is applied to biological matierals. On the basis of the total weight of the composition, a preferred composition comprises from about 0.5% to about 90% of a carbohydrate component and a protein component comprising about 0.5% to about 40% of a hydrolyzed protein of animal or plant protain. The biological matierals comprise alive, dead or debated virus, bacteria, yeast, cell culture, protein, peptide, vaccine, dryg or mixture thereof. The composition also comprises a carboxylic acid component accounting for 0.5% to 20% of the total weight of the composition. The carboxylic acid component comprises a glass strengthening a carboxylate. The composition of the invention allows drying and stabilizing of sensitive bioactive materials.
A total of 80 patients will randomly allocated into 2 groups, group A and placebo group using concealed envelope method.Group A patients (n= 40) will receive single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg. Patients in the placebo group (n=40) will receive as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.

General anesthesia will the institutional standards and all surgeries will be performed by the same surgical team.Standardized monitoring will be applied.After median sternotomy,CPB will be established with 1500 ml crystalloid priming volume and mild hypothermia (32°C) with a Trillium Affinity oxygenator (Medtronic,Minneapolis, Minnesota, USA) and a Sarns CPB machine (Harrison, Mt. Clemens, Michigan, USA) at a flow rate of 2.6 lmin-1m-2.Myocardial protection will be done using cold blood cardioplegia at 20°C. During CPB, homologous donor packed red blood cells will be transfused if hemoglobin was less than 6.5 gdl-1.During bypass, anticoagulation for extracorporeal circulation was performed using heparin 300 U/kg administered into the right atrium. Acelite activated clotting time (ACT) greater than 400 was considered adequate for commencing CPB; if less, an additional dose of 100Uof heparin will be adminstered.CPB will be conducted using nonocclusive roller pumps, arterial line filtration ,membrane oxygenators, , and blood-enriched cold hyperkalemic arrest. Systemic hypothermia documented by an esophageal temperature of 32°C will be maintained during aortic cross clamping.After completion of CPB and removal of the arterial cannula, heparin will be neutralized with 1 mg of protamine sulfate adminstered for every 100U of heparin over a period of 15 minutes . Eventually, a second dose of protamine 50 mg will be given if ACT remained above baseline. All patients will be transferred to ICU after surgery.
Each participant received 40-45 minutes long session, started in lying position. The therapeutic low-intensity pulsed ultrasound (US) was used for 7 minutes with the frequency of 1 MHz, Spatial Average Intensity was 0.2 W /cm2, pulsed duty cycle 20%, therapeutic dose was 112.5 J/cm2 with fixed application on the medial side of the knee joint. The model of US was Unit Intelect Mobile, (Chattanooga Inc). After US therapy passive stretching of calf, hamstring, quadriceps, hip flexors, adductors \& abductor s was done, which was followed by the manual strengthening exercises and strengthening with quadriceps bench. The session was repeated thrice a week and 12 sessions per month. The home program was guided in both groups including avoiding low sitting, cross leg sitting along with Isometrics of quadriceps atleast 3 times a day, with 5-10 seconds hold of each contraction.
The present invention relates to a neutralizing agent for toxicants, which comprises medical carbon and sorbitol. The neutralizer is used to minimize adverse effects of chemical or biological toxicants. First, a medical carbon intermediate is formed through a specific process according to the present invention to satisfy the formal standard of medical carbon defined by the Korean Pharmacopeia. Next, the medical carbon is dispersed/dissolved in aqueous sorbitol solution to be used as a neutralizer for toxicants for oral administration. In a rat group to which the neutralizer is not administered, all rats are died upon the administration of 7 ml of a liquid herbicide. However, in a rat test group to which the neutralizer is administered, a high survival rate (80%) is obtained. The present invention is completed based on the test result. The neutralizer for toxicants rapidly absorbs toxicants to remove the activity of harmful toxic ingredients in the stomach. The neutralizer for toxicants provided for oral administration in order to neutralize adverse effects of chemical or biological toxicants comprises medical carbon obtained according to the standard suitable for pharmacological mechanism. The medical carbon is pulverized into microparticles having a size of 0.1-100 μm. The medical carbon is added to 100 ml of an aqueous sorbitol solution in an amount 20 ± 5 g to provide a suspension. The aqueous sorbitol solution comprises sorbitol in an amount of 100 ± 20 mg per 100 cc of purified water.